- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Congressman Frank Pallone, Jr, on Expediting the FDA Drug Approval Process
Funding from the 21st Century Cures Act to the FDA will help expedite the drug approval process without sacrificing the accountability and effectiveness of the FDA's standards, said Congressman Frank Pallone, Jr (D-NJ).
In addition to funding for the Nationa Institutes of Health, the 21st Century Cures Act grants $550 million to the FDA for research and innovation specifically for drugs and medical devices, said Congressman Frank Pallone, Jr (D-NJ).
He believes that while this initiative expedite the process for a number of programs and clinical trials, it will maintain the accountability and effectiveness of the FDA’s standards.
“I was at the European Union about a month ago talking to the equivalent of the FDA in the European Union in Brussels and we’re the gold standard,” Mr Pallone said. “We’re the most rigorous process there is for both drugs and medical devices and I think that there are ways that maybe you can streamline that without limiting effectiveness.”
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
